Salix Stock Hits New 52-Week High (SLXP)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Salix Pharmaceuticals (Nasdaq: SLXP) hit a new 52-week high Friday as it is currently trading at $62.01, above its previous 52-week high of $61.92 with 119,901 shares traded as of 12:55 p.m. ET. Average volume has been 524,600 shares over the past 30 days.

Salix has a market cap of $3.73 billion and is part of the health care sector and drugs industry. Shares are up 50.5% year to date as of the close of trading on Thursday.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. The company has a P/E ratio of 50.3, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Salix as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Salix Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

Biotech Hits an Inflection Point

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

Put Agenus, Progenics on Your Small-Cap List

2 Small Biopharma Stocks on the Move

2 Small Biopharma Stocks on the Move